Professor Jacob Bornstein MD, MPA, is the Chairman of the Department of Obstetrics and Gynecology in Western Galilee Hospital-Nahariya, Israel. He is Full Professor and Associate Dean at the Bar-Ilan University, Faculty of Medicine.

Professor Bornstein has been the Chairman of the 2009-2011 Nomenclature Committee of the International Federation for Cervical Pathology and Colposcopy (IFCPC). He is on the Editorial Board of several American,

European and Israeli Scientific Journals and is the founder and director of the Israeli biennial course of lower genital tract diseases & colposcopy.

Dr. Darragh is an attending pathologist in University of California, San Francisco’s (UCSF) Department of Pathology. Her primary clinical and research interests are focused on HPV-associated anogenital tract disease.

She is board certified in Anatomic Pathology with an added qualification in Cytopathology. In addition to her clinical work in Anatomic Pathology, she is also an attending colposcopist in UCSF’s Dysplasia Clinic and has a joint appointment in the Department of Obstetrics, Gynecology and Reproductive Sciences.

Currently, Dr. Darragh is President of the American Society for Colposcopy and Cervical Pathology (ASCCP).

She is former chair of the ASCCP’s Pathology Committee and a former member of the College of American Pathologists (CAP) Cytopathology Resource Committee.

John Tidy is Honorary Professor of Gynaecological Oncology and Consultant Gynaecologist Oncologist at the Royal Hallamshire Hospital, Sheffield. He is a BSCCP certified colposcopist and a recognized specialist in gynaecological cancer surgery. He is currently the chairman of the NHS Cervical Screening Programme National Advisory Committee for Colposcopy and President-elect of the British Society for Colposcopy and Cervical Pathology. John is active in clinical research attracting funding from Cancer Research UK, World Cancer Research Fund International, NHS New and Emerging Technologies Program and the Pharmaceutical Industry.

Professor Frazer is internationally renowned for the co-creation of the technology for the cervical cancer vaccines, and began his career as a renal physician and clinical immunologist in Edinburgh, Scotland before emigrating in 1981 to Melbourne, Australia. He continued his clinical training and pursued studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay. In 1985, Professor Frazer accepted a teaching post with The University of Queensland and was appointed Director of The University of Queensland Diamantina Institute in 1991. In early 2011, Professor Frazer relinquished directorship of the Institute to commence in-post as CEO of the TRI. He retains an active research program at the Institute in immune responses to cancer and cancer immunotherapy.

Professor Frazer was awarded the 2005 CSIRO Eureka Prize for Leadership in Science and was selected as Queenslander of the Year, and Australian of the Year in 2006. He was also awarded the 2008 Prime Minister’s Prize for Science, the 2008 Balzan Prize for Preventive Medicine, the 2009 Honda Prize and in 2011, was elected as a Fellow of the esteemed Royal Society of London. In 2012, Professor Frazer was appointed a Companion of the Order of Australia (AC) in the Queen’s Birthday Honours.

Ian Hammond retired in 2012 after 30 years in clinical practice as a Gynaecologic Oncologist in Perth, WA.

In 2000 he developed (with John Taylor and Paul McMenamin) the Anatomy of Complications Workshop, that continues to assist colleagues avoid and manage complications of surgical practice. He was Chair of the Guidelines Review Group that developed the 2005 NHMRC guidelines for the management of abnormal Pap smears. Since 2011 he has been actively involved in the Renewal of the National Cervical Screening Program that has led to the MSAC recommendations regarding proposed innovative changes to the program.

He was recently appointed as Chair of the Steering Committee for the Renewal Implementation Project that has oversight for bringing the proposed changes into everyday clinical practice. In 2011 he was awarded the President’s Medal of the RANZCOG for services to Women’s Health.

Associate Professor Karen Canfell is an epidemiologist specialising in cancer screening. She obtained her D.Phil.

from the Cancer Epidemiology Unit at the University of Oxford. She now leads the Cancer Modelling Group at the Lowy Cancer Research Centre at UNSW and also chairs Cancer Council Australia’s screening advisory committee.

A focus of her research is the interplay between HPV vaccination and cervical screening in both developed countries and in low resource settings, and her group regularly perform evaluations of new cervical screening and diagnostic strategies for national government agencies in Australia, New Zealand and England. Her group performed the effectiveness modelling and economic evaluation for the major new national review (‘Renewal’) of cervical screening in Australia, and also recently performed a similar evaluation in England. Karen is also co-PI of Compass, a major new trial of cervical screening in the HPV-vaccinated population in Australia which is being performed through the Victorian Cytology Service.